Simplify Asset Management Inc. Raises Position in argenex SE $ARGX

Simplify Asset Management Inc. lifted its position in shares of argenex SE (NASDAQ:ARGX) by 87.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,115 shares of the company’s stock after buying an additional 1,456 shares during the period. Simplify Asset Management Inc.’s holdings in argenex were worth $2,620,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Capital World Investors increased its holdings in shares of argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after buying an additional 8,422 shares during the last quarter. M&T Bank Corp increased its holdings in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after buying an additional 774,916 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of argenex by 1.9% during the 3rd quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after buying an additional 6,259 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after buying an additional 250,278 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $806.46 on Monday. The stock has a fifty day moving average price of $767.17 and a 200 day moving average price of $815.79. The company has a market cap of $49.90 billion, a P/E ratio of 35.91, a P/E/G ratio of 1.28 and a beta of 0.46. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, sell-side analysts forecast that argenex SE will post 25.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Oppenheimer dropped their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Guggenheim upped their price objective on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Citizens Jmp upped their price objective on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,017.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.